The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | ENHANCE-2 and ENHANCE-3: exploring magrolimab combinations in AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, gives an overview of the ENHANCE-2 and ENHANCE-3 trials (NCT04778397; NCT05079230), which are evaluating doublet and triplet combinations with magrolimab in patients with acute myeloid leukemia (AML). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
